

Vaccination Recommendations for Updated 2024-2025 COVID-19 Vaccines^{1,2}

Age	Dose/Vial Color	Recommendation Based on COVID-19 Vaccination History ³
Pfizer/BioNTech Vaccine (<i>Comirnaty</i>) – mRNA vaccine		
6 months-4 years⁴	3 mcg/0.3 mL; yellow cap and label	Not previously vaccinated: <i>Three</i> doses: 1 st at week 0, 2 nd at week 3-8, and 3 rd ≥8 weeks after dose 2 ⁵ 1 previous Pfizer dose: <i>One</i> dose 3-8 weeks after 1 st dose and one dose ≥8 weeks after dose 2 ⁵ ≥2 previous Pfizer doses: <i>One</i> dose ≥8 weeks after last dose ⁵
5-11 years⁴	10 mcg/0.3 mL; light blue cap and label	Not previously vaccinated or Previously vaccinated: <i>One</i> dose
≥12-64 years	30 mcg/0.3 mL; gray cap and label	Not previously vaccinated or Previously vaccinated: <i>One</i> dose
≥65 years	30 mcg/0.3 mL; gray cap and label	Not previously vaccinated or Previously vaccinated: <i>Two</i> doses given 6 months apart (min 2 months apart)
Moderna Vaccine (<i>Spikevax</i>) – mRNA vaccine		
6 months-4 years⁴	25 mcg/0.25 mL; dark blue cap/green label	Not previously vaccinated: <i>Two</i> doses: 1 st at week 0 and 2 nd 4-8 weeks after 1 st dose ⁵ 1 previous Moderna dose: <i>One</i> dose 4-8 weeks after last dose ⁵ ≥2 previous Moderna doses: <i>One</i> dose ≥8 weeks after last dose
5-11 years⁴	25 mcg/0.25 mL; dark blue cap/green label	Not previously vaccinated or Previously vaccinated: <i>One</i> dose
≥12-64 years	50 mcg/0.5 mL; blue cap and label	Not previously vaccinated or Previously vaccinated: <i>One</i> dose
≥65 years	50 mcg/0.5 mL; blue cap and label	Not previously vaccinated or Previously vaccinated: <i>Two</i> doses given 6 months apart (min 2 months apart)
Novavax Vaccine – adjuvanted protein subunit vaccine		
≥12-64 years	5 mcg (plus 50 mcg adjuvant)/0.5 mL; blue cap/label	Not previously vaccinated: <i>Two</i> doses 8 weeks apart Previously vaccinated: <i>One</i> dose
≥65 years	5 mcg (plus 50 mcg adjuvant)/0.5 mL; blue cap/label	Not previously vaccinated: <i>Three</i> doses: 2 doses given 3-8 weeks apart ^{5,6} , followed by 1 additional dose of any COVID-19 vaccine given 6 months (min 2 months) after the last dose 1 previous Novavax dose: <i>Two</i> doses: One Novavax dose 3-8 weeks after 1 st dose ^{5,6} , followed by 1 additional dose of any COVID-19 vaccine given 6 months (min 2 months) after the last dose 2 previous Novavax doses: <i>Two</i> doses: 1 dose of any COVID-19 vaccine given 8 weeks after last Novavax dose, followed by 1 additional dose of any COVID-19 vaccine given 6 months (min 2 months) after the last dose

- The updated 2024-2025 formula vaccines include a monovalent component that more closely targets the JN.1 lineage of the Omicron variant (KP.2 strain in the Pfizer/BioNTech and Moderna vaccines and JN.1 strain in the Novavax vaccine). Previous bivalent and monovalent Moderna and Pfizer/BioNTech and monovalent Novavax vaccines are no longer authorized for use in the US. The Johnson & Johnson (Janssen) vaccine is no longer available in the US.
- For immunocompetent persons. Persons with moderate or severe immunocompromise are recommended to receive additional doses of the 2024-2025 COVID-19 formula vaccines (www.cdc.gov/vaccines/covid-19).
- Previously vaccinated includes vaccination with an age-appropriate previous version of a COVID-19 vaccine (not the 2024-2025 updated monovalent vaccine).
- Children who turn 5 years old during the initial vaccination series should receive 1 vaccine dose at the dosage for children 5-11 years old on or after turning 5 years old. All doses should be from the same manufacturer.
- According to the CDC, an 8-week interval between doses might be optimal for some patients, especially adolescent and young adult males, to reduce the risk of myocarditis and pericarditis.
- Any 2024-2025 COVID-19 vaccine can be administered if more than 8 weeks have elapsed since the first dose of Novavax vaccines was given.